Ikoma, Tatsuki http://orcid.org/0000-0003-3758-3425
Shimokawa, Mototsugu
Matsumoto, Toshihiko
Boku, Shogen
Yasuda, Tomoyo
Shibata, Nobuhiro
Kurioka, Yusuke
Takatani, Masahiro
Nobuhisa, Tetsuji
Namikawa, Tsutomu
Kitagawa, Hiroyuki
Hanazaki, Kazuhiro
Doi, Keitaro
Shimada, Takanobu
Tsumura, Takehiko
Marusawa, Hiroyuki
Kanaya, Seichiro
Morita, Shuko
Inokuma, Tetsurou
Nagai, Hiroki
Yasui, Hisateru
Satake, Hironaga http://orcid.org/0000-0001-7629-6803
Article History
Received: 24 October 2021
Accepted: 23 July 2022
First Online: 4 August 2022
Declarations
:
: Hironaga Satake received research funding from Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd., and honoraria from Bayer, Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo, Eli Lilly Japan, Merck Bio Pharma, MSD, Ono Pharmaceutical, Sanofi, Taiho Pharmaceutical Co., Ltd., Takeda, and Yakult Honsha. However, those funding sources had no involvement with our study. The rest of the authors do not have any conflict of interest.
: This study was conducted in accordance with the Helsinki Declaration of 1964 and later versions, and with the Ethical Guidelines for Clinical Studies. This study was approved by the institutional review boards of all three participating institutions: Kobe City Medical Center General Hospital (approval no. zn210501), Kansai Medical University Hospital, Kochi Medical School, Himeji Red Cross Hospital, and Osaka Red Cross hospital.
: The requirement for informed consent was waived owing to the retrospective nature of the study.